1,3-Diketone Analogs as Selective Lysyl Hydroxylase 2 (Lh2) Antagonists
Year: 2022
Type: preprint
Abstract: Lysyl hydroxylase 2 (LH2), an Fe(II) and α-ketoglutarate (αKG, also called 2-oxoglutarate, or 2OG)-dependent oxygenase, is an endoplasmic reticulum-resident enzyme that hydroxylates telopeptidyl lysine residues on fibrillar collagen molecules. It leads to the formation of hydroxylysine aldehyde-derived collagen cross-links (HLCCs), which are more stable than lysine aldehyde-derived collagen cross-links (LCCs) generated devoid of LH2. It has been reported that LH2 enhances lung cancer metastatic and invasive proclivity and modulates the types of collagen cross-links (HLCC-to-LCC) in the tumor stroma. Herein, we prepared a series of 1,3-diketone analogs 1–18 and identified 12 and 13 that inhibit the LH2-driven hydroxylation of a collagen peptide substrate with IC50 approximately 300 nM and 500 nM, respectively. 12 and 13 demonstrate a 9-fold selectivity for LH2 over LH1 and LH3. Quantum Mechanics/Molecular Mechanics (QM/MM) modeling indicates that in addition to the relatively stronger interactions between compounds 12 and 13 with the active site, the selectivity stems from non-covalent interactions like hydrogen bonding between the morpholine/piperazine rings with LH2-specific Arg661, where the corresponding residue in LH1 and LH3 is Pro. Migration assays in the 344SQ lung adenocarcinoma cell line reveal that 13 shows anti-migration activity.
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.4314687
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: green
Awards: G1144718286, Investigation of DNA Modifying Enzymes by Computational Simulations: Development and Applications, MRI: Acquisition of a High Performance Hybrid Computer Cluster for Computational Modeling, G3252379793, G3667714879, G52711424, G5363805725, G5748168713, G6375272071, MRI: Acquisition of a Computer Cluster for the Computational Chemistry Program at the University of North Texas, G7077335631, Targeted Therapeutic Drug Discovery & Development Program, G7678928379, G9000091155, G9000112290, G9000217152, G9000230098, University of Kentucky Center for Cancer Metabolism
OpenAlex ID: W4310523978
